Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 14Blood Pressure and Hypertension StudiesCardiovascular Health and Disease PreventionSodium Intake and Health

The DOI matches its Crossref record; the references it cites are not checked yet.

Clinical use of nifedipine GITS in the treatment of hypertension: an overview

Simon, Alain, Levenson, Jaime·2003·Expert Opinion on Pharmacotherapy
DOI 10.1517/14656566.4.1.95
Open this paper in CoChat — free account

Abstract

Given the major role of elevated blood pressure in the pathogenesis of both stroke and coronary heart disease, one of the biggest challenges facing public health authorities and medical practitioners is the control of hypertension worldwide, both in individual patients and at the population level. The prevalence of hypertension increases with age and is nearly 60% in people aged 65 - 74 years. With increasing age, polymorbidity and polypharmacy usually contribute to an increasingly complex approach to manage the respective clinical conditions, including the treatment of hypertension. All subgroups of calcium channel blockers are effective and well-tolerated in lowering blood pressure. They are of demonstrated benefit for the prevention of stroke in elderly patients with systolic hypertension. Calcium channel blockers are particularly recommended for elderly patients with systolic hypertension and for black patients. The nifedipine gastrointestinal therapeutic system (GITS) formulation provides a once-daily dosing regimen with a continuous and slow release of the drug, resulting in a smooth plasma concentration/time profile. The INSIGHT study established that nifedipine GITS decreased mortality and morbidity at the same level as standard diuretic treatment in hypertensive patients with additional risk factors. A subgroup analysis showed that the long-term protective effects of nifedipine GITS extended to hypertensive patients with diabetes mellitus and with previous myocardial infarction. Two substudies of INSIGHT showed that nifedipine slowed the progression of atherosclerosis in carotid arteries (intima-media thickness) and coronary arteries (coronary calcium) as compared to diuretic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14656566.4.1.95

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 49 · Cited by 14

Research works printed but not linked: 55

  1. UEMURA K, 1988, World Health Star Q., 41, 155
  2. JOFFRES MR, 2001, Am.' Hypertens., 14, 1099, 10.1016/S0895-7061(01)02211-7 · DOI
  3. MARQUES-VIDAL P, 1997, Hypertens., 11, 213
  4. PRIMATESTA P, 2001, Hypertension, 38, 827, 10.1161/hyp.38.4.827 · DOI
  5. CRUICKSHANK JM, 1987, Lancet, 1, 581, 10.1016/S0140-6736(87)90231-5 · DOI
  6. ABBOTT RD, 1987, The Honolulu Heart Program. JAMA, 257, 949
  7. STAMLER J, 1993, Diab. Care, 16, 434, 10.2337/diacare.16.2.434 · DOI · Paper page
  8. RAMSAY L, 1999, Hum. Hypertens., 13, 569, 10.1038/sj.jhh.1000917 · DOI
  9. STAESSEN JA, 1997, The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 350, 757
  10. HOCKERMAN GH, 1997, Anna. Rev Pharmacol Toxicol, 37, 361, 10.1146/annurev.pharmtox.37.1.361 · DOI
  11. ABERNETHY DR, 1999, N Engl. I Med., 341, 1447, 10.1056/NEJM199911043411907 · DOI
  12. LEVENSON JA, 1983, Hypertension, 5, V57–V60
  13. HILLEMAN DE, 1993, Clin. Ther., 15, 1002
  14. MOHIUDDIN SM, 1991, Carr. Titer. Res., 50, 546
  15. MYERS MG, 1994, Am. Hypertens., 7, 45A
  16. CROME P, 1993, Drug Invest., 5, 193, 10.1007/BF03258446 · DOI
  17. GUENGERICH FP, 1986, J. Biol. Chem., 261, 5051, 10.1016/S0021-9258(19)89213-X · DOI
  18. BRAVO EL, 1990, The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am. J. Hypertens., 3, 3265
  19. KRAKOFF LR, 1990, Hum. Hypertens., 4, 765
  20. ZANCHETTI A, 1994, Italian Nifedipine GITS Study Group. I Hypertens. Sapp], 12, 597
  21. FAGAN TC, 1994, Am. I Hypertens., 7, 39A
  22. LEVY B, 1993, Drug Invest., 5, 289, 10.1007/BF03259233 · DOI
  23. HOUSTON MC, 1991, Angiology, 42, 681, 10.1177/000331979104200901 · DOI
  24. LEON AS, 1993, Multicenter Cooperative Study Group. Clic. Ther., 15, 1094
  25. MANCIA G, 2002, Hypertens., 20, 545, 10.1097/00004872-200203000-00032 · DOI
  26. ZUSMAN RIVI, CHRISTENSEN DM, HIGGINS J, BOUCHER CA, 1991, I Cardiovasc. Pharmacol, 18, 843, 10.1097/00005344-199112000-00009 · DOI
  27. SCHNACK C, 1994, Acta Diabetol., 31, 14, 10.1007/BF00580754 · DOI
  28. GONG L, 1996, I Hypertens., 14, 1237, 10.1097/00004872-199610000-00013 · DOI
  29. LIU L, 1998, Systolic Hypertension in China (Syst-China) Collaborative Group. Hypertens., 16, 1823
  30. WANG JG, 2000, Systolic Hypertension in China (Syst-China) Collaborative Group. Arch. Intern. Med., 160, 211
  31. BROWN MJ, 2000, Lancet, 356, 366, 10.1016/S0140-6736(00)02527-7 · DOI
  32. COLLINS R, 1994, Br. Med. Bull., 50, 272, 10.1093/oxfordjournals.bmb.a072892 · DOI
  33. MOTRO M, 2001, Hypertension, 37, 1410, 10.1161/01.HYP.37.6.1410 · DOI
  34. SIMON A, 2001, Circulation, 103, 2949, 10.1161/01.CIR.103.24.2949 · DOI
  35. TSCHUDI MR, 1994, Circulation, 89, 2212, 10.1161/01.CIR.89.5.2212 · DOI
  36. LUBSEN J, 1997, ACTION Research Group. Br. I Clin. Eruct. Sapp], 88, 23
  37. TOAL CB, 1997, Can. Cardiol, 13, 921
  38. HELD PH, 1989, BMJ, 299, 1187, 10.1136/bmj.299.6709.1187 · DOI
  39. YUSUF S, 1991, Am. J. Cardiol, 67, 1295, 10.1016/0002-9149(91)90944-G · DOI
  40. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding, 1997, ' Hypertens, 15, 105
  41. NEAL B, 2000, Blood Pressure Lowering Treatment Trialists Collaboration. Lancet, 356, 1955
  42. CUTLER JA, 1998, N Engl. Med., 338, 679, 10.1056/NEJM199803053381009 · DOI
  43. PAHOR M, 1995, Am. Ceriatr. Soc., 43, 1191, 10.1111/j.1532-5415.1995.tb07393.x · DOI
  44. PAHOR M, 1996, Lancet, 348, 493, 10.1016/S0140-6736(96)04277-8 · DOI
  45. PAHOR M, 1996, Lancet, 347, 1061, 10.1016/S0140-6736(96)90276-7 · DOI
  46. PAHOR M, 1996, Hypertens., 9, 695, 10.1016/0895-7061(96)00186-0 · DOI
  47. PAHOR M, 1996, Gruppo Italian° di Farmacovigilanza nell Anziano (GIFA). Clin. Epidemiol, 49, 921
  48. STANTON AV, 1998, The jury is still out on whether they cause heart attacks and suicide. BMJ, 316, 1471
  49. FURBERG CD, 1996, Cardiovasc. Drugs Ther, 10, 463, 10.1007/BF00051111 · DOI
  50. PAHOR M, 2000, Lancet, 356, 1949, 10.1016/S0140-6736(00)03306-7 · DOI
  51. HANSSON L, 2000, Lancet, 356, 359, 10.1016/S0140-6736(00)02526-5 · DOI
  52. 10.1016/S0140-6736(99)10327-1 · DOI
  53. SCHUG BS, 2002, Br. J. Clin. Pharmacol, 53, 582, 10.1046/j.1365-2125.2002.01599.x · DOI
  54. BORHANI NO, 1996, A randomized controlled trial. JAMA, 276, 785
  55. ZANCHETTI A, 1998, Hypertens., 16, 1667, 10.1097/00004872-199816110-00014 · DOI

Metadata

Authors
Simon, A., & Levenson, J.
Affiliations
Hôpital Broussais (FR)
ORCID
Levenson, Jaime
Venue
Expert Opinion on Pharmacotherapy
Publisher
Informa Healthcare
Published
2003-01
Volume
4
Issue
1
Pages
95-106
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
DOI
10.1517/14656566.4.1.95
OpenAlex
W1970875566
Cited by
14
References
49
Citations by year
2024: 1 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 1
FWCI
0.44
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
nifedipine GITS, antihypertensive therapy, calcium channel blockers, once-daily dosing, INSIGHT trial, stroke prevention, systolic hypertension, elderly patients, Black patients, diabetes mellitus, myocardial infarction, atherosclerosis progression, carotid intima-media thickness, coronary artery calcium, diuretic comparison, morbidity and mortality
MeSH terms
Delayed-Action Preparations, Humans, Hypertension, Nifedipine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical use of nifedipine GITS in the treatment of hypertension: an overview. https://app.cochat.ai/papers/10.1517/14656566.4.1.95
The paper
Simon, A., & Levenson, J. (2003). Clinical use of nifedipine GITS in the treatment of hypertension: an overview. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.4.1.95

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.